Todd Morrison, MD
Family Medicine · Gardner, KSNPI 1194751172
Payments from drug & device makers
Across 261 payments — averaging $13.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$815
- Novo Nordisk$506
- Lilly USA, LLC$265
- Supernus Pharmaceuticals, Inc.$238
- AstraZeneca$208
- Pfizer$198
- plus $1K from 29 others
What the payments were for
- Food & beverage$3,47098%
- Education$582%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 73 | $815 |
| Novo Nordisk | 37 | $506 |
| Lilly USA, LLC | 16 | $265 |
| Supernus Pharmaceuticals, Inc. | 16 | $238 |
| AstraZeneca | 14 | $208 |
| Pfizer | 19 | $198 |
| GSK | 13 | $178 |
| Amgen(2 entities) | 10 | $147 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $124 |
| Axsome Therapeutics, Inc. | 5 | $84 |
| Krystal Biotech Inc | 4 | $71 |
| Boehringer Ingelheim | 5 | $66 |
| Corium, LLC | 5 | $61 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $49 |
| Amarin Pharma, Inc. | 4 | $48 |
| Otsuka America Pharmaceutical, Inc. | 3 | $43 |
| Sanofi-aventis U.S. LLC | 3 | $38 |
| Ardelyx, Inc. | 2 | $37 |
| Merck | 2 | $37 |
| Cranial Technologies, Inc | 2 | $33 |
| Amneal Pharmaceuticals LLC | 2 | $31 |
| Chiesi USA, Inc. | 1 | $29 |
| Medtronic | 1 | $23 |
| Abbott | 1 | $22 |
| Lundbeck LLC | 1 | $21 |
| Dexcom, Inc. | 1 | $21 |
| Upsher-smith Laboratories LLC | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Eisai Inc. | 1 | $17 |
| Antares Pharma, Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
| Cequr Corporation | 1 | $13 |
| Ironshore Pharmaceuticals Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $12 |
| Sanofi Pasteur Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$125
How this compares
$3,528 in reported general payments places this provider in the 80th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 108 | $116,382 |
| OzempicSemaglutide | 77 | $91,288 |
| FarxigaDapagliflozin Propanediol | 86 | $81,423 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 110 | $80,809 |
| TrulicityDulaglutide | 37 | $57,714 |
| JardianceEmpagliflozin | 60 | $50,259 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 65 | $38,498 |
| XareltoRivaroxaban | 41 | $27,164 |
| LinzessLinaclotide | 24 | $20,590 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 15 | $19,251 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 17 | $18,586 |
| TradjentaLinagliptin | 21 | $17,991 |
| JanuviaSitagliptin Phosphate | 13 | $16,202 |
| Repatha SureclickEvolocumab | 25 | $15,867 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $15,633 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta | $178 | $119,306175 claims |
| PfizerEliquis | $198 | $116,382108 claims |
| Novo NordiskOzempic, Xultophy 100-3.6 | $506 | $110,53992 claims |
| AstraZenecaFarxiga | $208 | $81,42386 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $66 | $73,72192 claims |
| Lilly USA, LLCTrulicity | $265 | $57,71437 claims |
| Johnson & JohnsonXarelto | $12 | $27,16441 claims |
| AbbVieLinzess | $815 | $20,59024 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $38 | $18,58617 claims |
| MerckJanuvia | $37 | $16,20213 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $31 | $1,805253 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Gardner
- Terry PolingWichita$24.2M
- Richard GloverNewton$19.6M
- Daniel DickersonLenexa$13.6M
- Patrick YaoOlathe$11.7M
- Michael RauschAugusta$8.1M
- Terry KleinWichita$5.9M
- Richard EgelhofWichita$4.1M
- Thomas KleinWichita$3.4M
- Troy HoldemanNewton$3.2M
- Stacy SlechtaNewton$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.